Last reviewed · How we verify

Diuretics plus human albumin — Competitive Intelligence Brief

Diuretics plus human albumin (Diuretics plus human albumin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Diuretic + colloid combination therapy. Area: Hepatology; Nephrology; Critical Care.

marketed Diuretic + colloid combination therapy Hepatology; Nephrology; Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Diuretics plus human albumin (Diuretics plus human albumin) — University of Bologna. Diuretics promote fluid and sodium excretion while human albumin expands plasma volume and maintains oncotic pressure to counteract fluid shifts.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diuretics plus human albumin TARGET Diuretics plus human albumin University of Bologna marketed Diuretic + colloid combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Diuretic + colloid combination therapy class)

  1. University of Bologna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diuretics plus human albumin — Competitive Intelligence Brief. https://druglandscape.com/ci/diuretics-plus-human-albumin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: